Two Targets, One Drug for New EGFR Inhibitors
Open Access
- 16 August 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 98 (16) , 1102-1103
- https://doi.org/10.1093/jnci/djj350
Abstract
The new drug that garnered the most media attention at this year's American Society of Clinical Oncology meeting was lapatinib (Tykerb), a targeted agent that showed a tumor response in metastatic breast cancer resistant to trastuzumab (Herceptin). In an international phase III trial, lapatinib with capecitabine significantly improved the time to progression compared with capecitabine alone. The findings prompted early closing of the trial and put lapatinib on track for regulatory review later this year.Keywords
This publication has 0 references indexed in Scilit: